{"key":"op_800_ES","page":{"url":"https://fr.bookimed.com/clinics/country=spain/procedure=car-t-cell-therapy/","procedure":{"id":800,"slug":"car-t-cell-therapy","name":"Thérapie CAR T","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"hematology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":34,"iso":"ES","name":"Espagne"},"currency":"USD","data_date":"2026-09-26"},"pages":{"clinics_url":"https://fr.bookimed.com/clinics/country=spain/procedure=car-t-cell-therapy/","cost_url":"https://fr.bookimed.com/clinics/country=spain/procedure=car-t-cell-therapy/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":380000,"to":520000,"avg":{"value":383383.80714645435,"method":"median","source":"clinics"},"us":{"from":420000,"to":540000},"uk":{"from":330000,"to":420000},"by_technique":{"status":"missing","reason":"not_collected"},"by_city":[{"city":"Pampelune","from":380000},{"city":"Barcelone","from":388300},{"city":"Alicante","from":280000},{"city":"Madrid","from":230000}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":90000,"to":150000},{"country_iso":"FR","from":295000,"to":385000},{"country_iso":"GB","from":330000,"to":420000},{"country_iso":"US","from":420000,"to":540000},{"country_iso":"IL","from":84000,"to":405000},{"country_iso":"TR","from":150000,"to":220000},{"country_iso":"MX","from":120000,"to":185000},{"country_iso":"DE","from":285000,"to":365000},{"country_iso":"CA","from":340000,"to":470000},{"country_iso":"AE","from":190000,"to":310000},{"country_iso":"TH","from":150000,"to":220000},{"country_iso":"PL","from":165000,"to":230000},{"country_iso":"KR","from":220000,"to":300000},{"country_iso":"CZ","from":150000,"to":195000},{"country_iso":"AT","from":280000,"to":365000},{"country_iso":"IT","from":400000,"to":650000},{"country_iso":"CN","from":275000,"to":319000},{"country_iso":"AU","from":330000,"to":420000},{"country_iso":"IN","from":38000,"to":70000},{"country_iso":"MY","from":120000,"to":180000},{"country_iso":"VN","from":150000,"to":230000},{"country_iso":"BR","from":280000,"to":400000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":10,"variant":"ranges_overlap"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":5,"items":[{"id":272,"name":"SJD Barcelona Children’s Hospital","city":"Barcelona","rating":4.7,"reviews_count":44,"accreditations":["Bookimed Award: Best pediatric hospital","World's Best Specialized Hospitals 2022 by Newsweek"],"rank":1,"has_procedure":true,"why_ranked":"First paediatric hospital in Spain authorized to offer CART-19 for refractory leukaemia and high-risk ALL. HEPA-filtered isolation rooms and SEGUIM survivor unit support safety and long-term monitoring.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":78,"name":"Centro Médico Teknon","city":"Barcelona","rating":4.7,"reviews_count":497,"accreditations":["Joint Commission International","European Foundation for Quality Management","THE IMTJ MEDICAL TRAVEL AWARD WINNER IN 2019","Patient choice in Neurology","Patient choice in Neurosurgery","Patient choice for Epilepsy treatment","World's Best Hospitals 2021 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":"Specializes in CAR T-cell therapy with experienced hematologists. Offers comprehensive treatment phases from diagnostics to follow-up, including KYMRIAH infusion. JCI-accredited facility with 94% patient recommendation rate.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":278,"name":"Quironsalud Madrid","city":"Madrid","rating":3.8,"reviews_count":6,"accreditations":["World's Best Hospitals 2021 by Newsweek"],"rank":3,"has_procedure":true,"why_ranked":"National reference center authorized by Spanish Ministry of Health. Doctors have performed 900+ CAR-T procedures. Offers personalized programs for complex pediatric cases.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":6225,"name":"Hospital Ruber Internacional","city":"Madrid","rating":5,"reviews_count":3,"accreditations":["Joint Commission International","International Organization for Standardization"],"rank":4,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":339,"name":"Clinica Universidad de Navarra (Navarra Hospital)","city":"Pamplona","rating":4.7,"reviews_count":7,"accreditations":["Joint Commission International","European Society for Medical Oncology","World's Best Hospitals 2020 by Newsweek","World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2022 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek"],"rank":5,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":5,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":366,"slug":"pamplona","name":"Pampelune","clinics_count":1,"price_from":380000,"profile":{"status":"missing","reason":"not_collected"}},{"id":98,"slug":"barcelona","name":"Barcelone","clinics_count":1,"price_from":388300,"profile":{"city_type":"Mediterranean coastal city in Spain","access":["Barcelona Airport (BCN), 15 km southwest of city center"],"sources":["https://en.wikipedia.org/wiki/Barcelona","https://en.wikipedia.org/wiki/Barcelona–El_Prat_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":441,"slug":"alicante","name":"Alicante","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":280000,"profile":{"city_type":"Mediterranean port city in Spain","access":["Alicante Airport (ALC), 9 km from the city"],"sources":["https://en.wikipedia.org/wiki/Alicante","https://en.wikipedia.org/wiki/Alicante%E2%80%93Elche_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":346,"slug":"madrid","name":"Madrid","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":230000,"profile":{"city_type":"Capital and largest city of Spain","access":["Madrid Barajas Airport (MAD), 13 km from Puerta del Sol"],"sources":["https://en.wikipedia.org/wiki/Madrid","https://en.wikipedia.org/wiki/Madrid–Barajas_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":{"status":"missing","reason":"no_offers"},"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":{"status":"missing","reason":"no_offers"},"packages":{"status":"missing","reason":"no_offers"},"related_packages":{"status":"missing","reason":"no_offers"},"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"operation_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"hospital_nights":{"value":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"source":"parsed_details"},"treatment_conditions":["inpatient"],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"horizon":"Best response, typically assessed at 1-3 months after infusion","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"days_in_clinic":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","revision_rate_pct":null,"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"unit":"percent","horizon":"Best response, typically assessed at 1-3 months after infusion","evidence_status":"limited","population":"Adults with relapsed/refractory LBCL after two or more prior lines"},"techniques":[{"name":"Autologous CD19-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"name":"Autologous BCMA-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","recovery":"Similar monitoring; prolonged cytopenias are common."}],"treatment_conditions":["inpatient"],"treatment_duration_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"initial_assessment_documents":["Pathology report with CD19 or BCMA status","Summary of prior treatment lines and responses","Recent PET-CT or MRI report","Bone marrow biopsy report","Recent CBC, kidney and liver function tests","Echocardiogram report (if available)"],"travel_trips":{"min":1,"max":2,"one_trip_possible":true,"qualifier":"Cell collection, then 3-9 weeks manufacturing, usually at home; return for infusion and 4+ weeks nearby. One trip means staying."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1}}},"techniques":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Similar monitoring; prolonged cytopenias are common."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-11","next_check_at":"2027-02-09"},"travel":{"status":"ok","items":[{"id":"V1","item":"passport_validity","audience":"uk","volatile":true,"text":"The passport must have an expiry date at least 3 months after you plan to leave the Schengen area","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/entry-requirements","host":"gov.uk","quote":"have an ‘expiry date’ at least 3 months after the day you plan to leave the Schengen area (the expiry date does not need to be within 10 years of the date of issue)","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"medicines","audience":"all","volatile":false,"text":"Carry prescription medication in its original packaging, along with your doctor's prescription","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Always carry your prescription medication in original packaging, along with your doctor’s prescription.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"prescriptions","audience":"us","volatile":false,"text":"Medications that require a prescription in the United States also require a local doctor's prescription in Spain","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Medications requiring prescriptions in the United States also require a local doctor’s prescription in Spain.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V4","item":"ghic","audience":"uk","volatile":false,"text":"A GHIC or EHIC is needed to get medically necessary state healthcare in Spain","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/health","host":"gov.uk","quote":"To get medically necessary state healthcare in Spain, you need a Global Health Insurance Card ( GHIC ) or a European Health Insurance Card ( EHIC ).","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V5","item":"hospital_payment","audience":"all","volatile":false,"text":"Private hospitals usually require payment or proof of insurance or funds before admitting a patient","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Private hospitals usually require payment or proof insurance or funds before admitting a patient.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V6","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 112 and ask for an ambulance","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/health","host":"gov.uk","quote":"Dial 112 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["austria","china","germany","israel","italy","lithuania","republic-of-korea","turkey","united-kingdom","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.69,"count":557,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>CAR T-cell therapy in Spain typically costs from _op_800_price_from_ to _op_800_price_to_. Prices primarily depend on whether the treatment uses commercial products or hospital-developed academic protocols. Patients save around _price_percent_discount_% compared to the US, where this procedure costs _price_compare_US_average_ on average. Quotes in Spain usually include T-cell collection, genetic engineering, chemotherapy, and a 20-30 day inpatient stay for monitoring.</p>\n\n<ul>\n<li><strong>Commercial drug therapy:</strong> _op_800_price_from_ to _op_800_price_to_ for approved products like Kymriah and Yescarta.</li>\n<li><strong>Hospital-developed protocols:</strong> Often 70-75% cheaper than commercial options through specialized European \"Hospital Exemption\" programs.</li>\n<li><strong>Clinical trials:</strong> Some centers like Quironsalud Madrid offer potential cost reductions through active oncology trials.</li>\n<li><strong>Location factors:</strong> Major medical hubs for this therapy include Barcelona, Madrid, and Pamplona.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Spain offers exceptional value because private centers like Centro Médico Teknon and Clinica Universidad de Navarra are JCI-accredited. Navigating these institutions is smart. Clinica Universidad de Navarra has a 74% bone sarcoma cure rate. While commercial drugs remain expensive, Spanish hospitals are pioneers in low-cost academic CAR T-cell manufacturing. SJD Barcelona Children's Hospital is a top 3 European pediatric center. It is ideal for families seeking specialized pediatric hematologists like Dr. Susana Rives Sola.</p>","faq":[{"q":"Who is eligible for CAR T-cell therapy in Spain?","a":"<p>Eligibility for CAR T-cell therapy in Spain is reserved for patients with relapsed or refractory hematological cancers who have exhausted standard treatments. Candidates typically include those with diffuse large B-cell lymphoma, B-cell acute lymphoblastic leukemia, or multiple myeloma after failing two or more therapy lines.</p> <ul> <li><strong>Clinical indications:</strong> Patients must have specific lymphoma, leukemia, or myeloma diagnoses.</li> <li><strong>Treatment history:</strong> Therapy is usually a second or third-line option after standard failures.</li> <li><strong>Health status:</strong> Candidates require adequate organ function and a stable ECOG performance score.</li> <li><strong>Authorized centers:</strong> Treatment occurs only at designated CSUR hubs in Barcelona, Madrid, or Pamplona.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain stands out for its academic CAR T-cell programs like ARI-0001, which are developed within public hospitals under hospital exemption rules. This allows centers like SJD Barcelona Children’s Hospital to offer cutting-edge cellular therapy variations that may not be available elsewhere, providing a critical alternative for pediatric patients.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the importance of early consultation with a cellular therapist, as T-cell apheresis capacity often becomes a bottleneck for accessing timely care.</p>"},{"q":"How effective is CAR T-cell therapy in Spanish clinics?","a":"<p>CAR T-cell therapy in Spain is highly effective, with remission rates reaching 84% to 87% for specific leukemia types. Spanish clinics lead in academic CAR-T development, offering outcomes comparable to commercial products while maintaining a high 12-month survival rate of approximately 80%.</p> <ul> <li><strong>Remission rates:</strong> ARI-0001 therapy achieves 87% complete remission within three months.</li> <li><strong>Survival outcomes:</strong> Specialized clinics report a 12-month overall survival rate of 80%.</li> <li><strong>Treatment safety:</strong> Severe cytokine release syndrome occurs in only 12% of patients.</li> <li><strong>Clinical availability:</strong> Over 7 clinics in Spain now administer 7 different CAR-T products.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain’s leadership in academic CAR-T therapy, such as the ARI-0001 protocol at Barcelona centers, provides a significant accessibility advantage. While commercial CAR-T can cost _op_800_price_to_, Spain's academic versions offer a high-efficacy alternative often unavailable in other European medical hubs.</p> <p><strong>Patient Consensus:</strong> Patients value how Spanish university clinics provide CAR-T as a standard treatment. Those with advanced lymphoma specifically seek out Barcelona centers for specialized CD30 CAR-T trials.</p>"},{"q":"Is CAR T-cell therapy available in Spain?","a":"<p>CAR T-cell therapy is widely available in Spain through advanced clinical trials and approved hospital-developed programs like ARI-0001. Leading facilities in Barcelona, Madrid, and Pamplona provide these cellular immunotherapies for hematologic malignancies including leukemia, lymphoma, and multiple myeloma.</p> <ul> <li><strong>Treatment availability:</strong> Clinics offer CD30, ARI, and Anito-cell therapies for relapsed blood cancers.</li> <li><strong>Leading institutions:</strong> JCI-accredited centers like Teknon and SJD Barcelona Children’s Hospital lead research.</li> <li><strong>Regulatory oversight:</strong> The Spanish Agency of Medicines and Medical Devices (AEMPS) authorizes all academic protocols.</li> <li><strong>Cost structure:</strong> Therapy in Spain ranges from _op_800_price_from_ to _op_800_price_to_.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain’s unique hospital exemption pathway allows academic centers to develop their own CAR-T versions legally. This leads to significantly lower costs than US commercial drugs. While the US average is _price_compare_US_average_, choosing Spanish academic programs can save you approximately _price_percent_discount_% while maintaining high safety standards.</p> <p><strong>Patient Consensus:</strong> Patients value Spain as an affordable alternative to US costs, especially for experimental treatments. Many emphasize checking clinical trial eligibility early, particularly for late-relapse multiple myeloma therapy.</p>"},{"q":"How long does the CAR T-cell process take?","a":"<p>The total CAR T-cell process in Spain typically takes 6 to 8 weeks from enrollment to infusion. While the actual cell infusion takes under 1 hour, the timeline includes leukapheresis, genetic engineering, and mandatory 30-day post-treatment monitoring to manage potential side effects.</p> <ul> <li><strong>Evaluation period:</strong> Doctors confirm eligibility and cancer type over 5 to 7 days.</li> <li><strong>Cell collection:</strong> Leukapheresis harvesting T-cells from the blood takes 3 to 4 hours.</li> <li><strong>Lab manufacturing:</strong> Genetic modification and cell expansion require 2 to 3 weeks.</li> <li><strong>Lymphodepletion phase:</strong> Chemotherapy prepares the body for new cells over 3 days.</li> <li><strong>Clinical monitoring:</strong> Patients stay near JCI-accredited facilities for roughly 30 days post-infusion.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain offers a unique dual-track for timelines. While standard-of-care manufacturing is fixed, clinics like Quironsalud Madrid provide clinical trial access. These experimental protocols sometimes offer faster enrollment but require specialized pediatric hematologists like those at SJD Barcelona.</p> <p><strong>Patient Consensus:</strong> Patients emphasize that waiting for lab results is the most stressful phase. Many suggest preparing for a full 2-month stay in Spain to ensure safe recovery.</p>"},{"q":"Where can I receive CAR T-cell therapy in Spain?","a":"<p>Spain offers CAR T-cell therapy at JCI-accredited centers in Barcelona and Madrid, specializing in advanced cellular immunotherapy for leukemia and lymphoma. Leading facilities include Centro Médico Teknon and Hospital Clínic de Barcelona, which pioneered academic CAR-T protocols like ARI-0001 for adult and pediatric oncology patients.</p> <ul> <li><strong>Specialized oncology centers:</strong> Centro Médico Teknon and SJD Barcelona Children’s Hospital provide pediatric and adult care.</li> <li><strong>Expert hematology units:</strong> Doctors at HM Montepríncipe and Teknon have over 20 years of immunotherapy experience.</li> <li><strong>Advanced research access:</strong> Quironsalud Madrid offers clinical trials for patients seeking experimental third-generation CAR-T therapies.</li> <li><strong>Quality certifications:</strong> Clinics like Hospital Ruber Internacional maintain JCI, ISO 9001, and ISO 14001 standards.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain is a global leader in academic CAR-T development, not just commercial pharmaceutical versions. Data shows clinics like SJD Barcelona Children’s Hospital serve 450,000 patients annually and participate in groundbreaking trials. For patients, this often means access to innovative third-generation CAR-T (Ainto-cell) which aims to reduce neurotoxicity risks.</p> <p><strong>Patient Consensus:</strong> Patients emphasize checking clinical trial eligibility for specific conditions like CD30 lymphoma or multiple myeloma. They focus on the high success rates in Spanish studies, noting complete remission in 60% of experimental cases.</p>"},{"q":"Can a non-resident receive CAR T-cell therapy in Spain?","a":"<p>Non-residents can receive CAR T-cell therapy in Spain through the private healthcare sector or clinical research pathways. International patients typically access this immunotherapy at designated centers regulated by the Spanish Agency of Medicines and Medical Devices, often by utilizing hospital exemption rules for in-hospital cell manufacturing.</p> <ul> <li><strong>Available facilities:</strong> Approximately 14 specialized centers like Clinica Universidad de Navarra provide CAR-T.</li> <li><strong>Eligible conditions:</strong> Doctors treat specific relapsed or refractory blood cancers, including leukemias and lymphomas.</li> <li><strong>Surgeon expertise:</strong> Specialists like Dr. Francesc Cobo Valien have over 25 years of hematology experience.</li> <li><strong>Treatment range:</strong> Options include commercial products, biological therapies, and clinical trial-based research protocols.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain is a global leader in academic CAR-T development through the hospital exemption pathway. This allows clinics to produce cellular therapies on-site rather than relying strictly on pharmaceutical manufacturers. For patients, this creates more opportunities to join innovative clinical trials at centers like Quironsalud Madrid or SJD Barcelona.</p> <p><strong>Patient Consensus:</strong> Patients often find that clinical trials are the most viable path for long-term care. Navigating medical immigration and visa logistics remains the primary challenge for those traveling from outside the European Union.</p>"}],"h2":[{"text":"Comment ça fonctionne","kind":"content"},{"text":"Quel est le Coût pour votre Thérapie CAR T en Espagne ?","kind":"content"},{"text":"Découvrez les Meilleures Cliniques pour Votre Thérapie CAR T en Espagne : 5 Options Vérifiées et Prix","kind":"content"},{"text":"Aperçu de thérapie CAR T en Espagne","kind":"content"},{"text":"Obtenez une évaluation médicale pour Thérapie CAR T en Espagne : Choisissez le meilleur spécialiste dans le domaine","kind":"content"},{"text":"Avis sur Bookimed : Découvrez l'Expérience des Patients","kind":"content"},{"text":"Partager ce contenu","kind":"content"},{"text":"Histoires vidéo des patients de Bookimed","kind":"content"},{"text":"FAQ de thérapie CAR T en Espagne","kind":"content"},{"text":"Obtenez une consultation gratuite","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}